IL115224A0 - Preparations for use in the treatment of osteoporosis - Google Patents

Preparations for use in the treatment of osteoporosis

Info

Publication number
IL115224A0
IL115224A0 IL11522495A IL11522495A IL115224A0 IL 115224 A0 IL115224 A0 IL 115224A0 IL 11522495 A IL11522495 A IL 11522495A IL 11522495 A IL11522495 A IL 11522495A IL 115224 A0 IL115224 A0 IL 115224A0
Authority
IL
Israel
Prior art keywords
osteoporosis
preparations
treatment
Prior art date
Application number
IL11522495A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of IL115224A0 publication Critical patent/IL115224A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11522495A 1994-09-09 1995-09-08 Preparations for use in the treatment of osteoporosis IL115224A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30392594A 1994-09-09 1994-09-09

Publications (1)

Publication Number Publication Date
IL115224A0 true IL115224A0 (en) 1995-12-31

Family

ID=23174289

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11522495A IL115224A0 (en) 1994-09-09 1995-09-08 Preparations for use in the treatment of osteoporosis

Country Status (8)

Country Link
EP (1) EP0779812A4 (ko)
JP (1) JPH10505090A (ko)
KR (1) KR970705400A (ko)
CN (1) CN1157565A (ko)
AU (1) AU686458B2 (ko)
CA (1) CA2199252A1 (ko)
IL (1) IL115224A0 (ko)
WO (1) WO1996007417A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US8052987B2 (en) 2000-06-20 2011-11-08 Novartis Pharmaceuticals Corporation Method of administering bisphosphonates
WO2007059470A2 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
HUE034784T2 (en) 2009-07-31 2018-02-28 Gruenenthal Gmbh Crystallization process and bioavailability
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114473T1 (de) * 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4868164A (en) * 1986-12-19 1989-09-19 Norwich Eaton Pharmaceuticals, Inc. Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
US5403824A (en) * 1993-03-19 1995-04-04 The Procter & Gamble Company Methods for the treatment of osteoporosis

Also Published As

Publication number Publication date
JPH10505090A (ja) 1998-05-19
WO1996007417A1 (en) 1996-03-14
CN1157565A (zh) 1997-08-20
EP0779812A1 (en) 1997-06-25
EP0779812A4 (en) 1997-09-10
AU3547595A (en) 1996-03-27
CA2199252A1 (en) 1996-03-14
AU686458B2 (en) 1998-02-05
KR970705400A (ko) 1997-10-09

Similar Documents

Publication Publication Date Title
EG24222A (en) Spiro-azabicyclic compounds useful in therapy
GB9407135D0 (en) Treatment of osteoporosis
SG99279A1 (en) Myoblast therapy for cosmetic treatment
GB9411080D0 (en) Treatment
GB9415996D0 (en) Therapeutic agents
ZA952356B (en) Skin treatment composition
GB9416189D0 (en) Therapeutic agents
ZA95556B (en) Combination treatment for osteoporosis
GB9423868D0 (en) Compounds for use in medicine
GB9423460D0 (en) Therapeutic agents
GB9416467D0 (en) Compounds for use in medicine
GB9414157D0 (en) Medical use
IL115224A0 (en) Preparations for use in the treatment of osteoporosis
GB9424694D0 (en) Compounds for use in medicine
ZA952121B (en) Skin treatment composition
IL115225A0 (en) Preparations containing estrogen compounds for use in the treatment of osteoporosis
IL115223A0 (en) Preparation containing antiresorptive compounds for use in the treatment of osteoporosis
GB9401879D0 (en) Therapeutic agents
ZA952120B (en) Skin treatment composition
GB9219776D0 (en) New compounds for use in the treatment of cancer
ZA951420B (en) Therapeutic agents
GB9625449D0 (en) Compounds for use in medicine
ZA957122B (en) Spiro-azabicyclic compounds useful in therapy
GB9411244D0 (en) Compounds useful in therapy
GB9422497D0 (en) Compounds useful in therapy